Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Direct oral anticoagulants and reversal

Haematology and transfusion · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Life-threatening DOAC-associated bleeding

Critical-site haemorrhage, shock, uncontrolled loss or bleeding that cannot wait for drug clearance requires simultaneous resuscitation, anatomical source control and agent-specific reversal assessment.

Action: Stop the DOAC, document drug, dose and last ingestion, send FBC, renal, liver, PT, APTT, fibrinogen, group and a calibrated drug level if rapidly available, involve haematology and the procedural team, then use idarucizumab for dabigatran or the supported factor-Xa strategy under current national and local policy.

Synopsis

Prescribe factor Xa and direct thrombin inhibitors by indication and organ function, recognise clinically relevant residual effect and use specific reversal only when bleeding or urgent surgery justifies it.

  • DOAC doses are indication specific: never transfer an atrial-fibrillation reduction rule to acute VTE or mistake an extended-prevention dose for initial treatment.
  • Use Cockcroft–Gault creatinine clearance, not unadjusted laboratory eGFR, and repeat it during acute illness because drug accumulation can change within hours.
  • Apixaban and rivaroxaban start acute VTE with intensified oral regimens; dabigatran and edoxaban require at least 5 days of therapeutic parenteral anticoagulation first.
  • A normal PT or APTT does not reliably exclude a clinically relevant apixaban or rivaroxaban concentration; thrombin time is highly sensitive to dabigatran but is not quantitative.
  • Idarucizumab 5 g IV is the specific first-line reversal for dabigatran when bleeding is life-threatening or uncontrolled or urgent surgery cannot wait.
  • Andexanet alfa is licensed for adult apixaban- or rivaroxaban-associated life-threatening or uncontrolled bleeding; dose depends on the factor Xa inhibitor dose and time since ingestion.
  • NICE TA697 recommends andexanet within its defined commissioned population for uncontrolled or life-threatening gastrointestinal bleeding; other sites require current national and local specialist policy.
  • Four-factor PCC has no licensed DOAC-neutralising action but may be used off label for severe factor-Xa-inhibitor bleeding when specific reversal is unavailable or inappropriate under a haematology protocol.
  • Activated charcoal can reduce absorption after a recent ingestion when the airway is protected; dialysis can remove dabigatran but not highly protein-bound factor Xa inhibitors.
  • After haemostasis, reassess early restart: unnecessary prolonged interruption exposes the patient to recurrent VTE, cardioembolic stroke or valve-related thrombosis.

Key red flags

Intracranial, spinal, pericardial, retroperitoneal or airway bleeding requires immediate multidisciplinary action even if haemoglobin and routine coagulation tests are initially reassuring.

Acute kidney injury, overdose, strong P-glycoprotein or CYP3A4 inhibition, very low weight or an unknown last dose increases the chance of clinically important residual anticoagulant activity.

Thrombosis, ischaemia or heparin unresponsiveness can follow andexanet; reversal does not remove the underlying thrombotic indication and must be followed by a restart assessment. BSH 2026 warns that thromboembolic risk, particularly ischaemic stroke, may outweigh benefit; assess this before selecting andexanet.

Investigation priorities

01
First-line: exposure, FBC and organ profileFirst stepFirst line

Estimate residual effect, blood loss and clearance capacity.

Management branches

Dabigatran emergencyUse specific neutralisation

Dabigatran exposure accompanies life-threatening or uncontrolled bleeding or surgery that cannot safely wait.

  1. Stop dabigatran, resuscitate, control the source and record last dose, renal function, thrombin time and drug level if rapidly available.
  2. Give idarucizumab 5 g IV as two consecutive 2.5 g doses while definitive haemostasis proceeds.
  3. Monitor for recurrent bleeding or rebound, then reassess renal function, correct dose and restart when haemostasis and thrombotic risk permit.

Key medicines

IdarucizumabGive 5 g intravenously as two consecutive 2.5 g/50 mL infusions over 5–10 minutes each or bolus injections for dabigatran-associated life-threatening or uncontrolled bleeding or urgent surgery.It does not reverse factor Xa inhibitors or other coagulopathy. Monitor for rebound in renal failure or overdose and for thrombosis after reversal; consider another 5 g only for supported recurrent-effect scenarios with specialist input.
Andexanet alfa low doseGive 400 mg intravenously at about 30 mg/min, immediately followed by 4 mg/min for 120 minutes when the last apixaban or rivaroxaban dose and timing meet the low-dose table.Use the SmPC dose table rather than guessing from bleed severity. Thromboembolism, myocardial infarction, stroke and cardiac arrest occur; it can cause heparin unresponsiveness and is not licensed for edoxaban, LMWH or routine urgent-surgery pretreatment.
Open full textbook →Answer 2 questions
Sources and review status7 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • MHRA DOAC bleeding and reversal reminderUK safety advice on bleeding risk and available reversal agents.
  • Praxbind Summary of Product CharacteristicsLicensed idarucizumab indications, 5 g regimen and repeat-dose conditions.
  • Ondexxya Summary of Product CharacteristicsLicensed andexanet population, low and high regimens and safety limitations.
  • NICE TA697 andexanet alfa recommendationsNHS use within NICE's defined gastrointestinal-bleeding recommendation.
  • MHRA renal function estimate for DOAC dosingCockcroft–Gault calculation in renal impairment.
  • BSH position statement on andexanet alfa, April 2026Current UK benefit-risk warning and recommendation to use andexanet only within its licensed indication.
  • SMC2273 andexanet alfa interim acceptanceNHSScotland interim acceptance for the licensed indication, subject to the specified access arrangement; distinct from NICE GI-only recommendation.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. ·

Report a content problem
Content changes
Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom